scholarly journals Association Between Body Composition and Bone Density in Morbidly Obese Women According to Menopausal Status (P01-023-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Marise Crivelli ◽  
Amina Chain ◽  
Flavia Bezerra
Keyword(s):  
Body Composition ◽  
Lumbar Spine ◽  
Soft Tissue ◽  
Bone Density ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Lean Mass ◽  
Severe Obesity ◽  
Menopausal Status ◽  
Morbidly Obese

Abstract Objectives The study aim was to assess bone mineral density (BMD) and bone turnover in pre- and postmenopausal women with severe obesity. Additionally, we explored the association between soft tissue body composition and BMD according to menopausal status. Methods This is a cross-sectional study conducted in pre- (n = 37) and postmenopausal (n = 22) morbid obese (BMI >40 kg/cm2) women. Body composition and BMD at different sites (lumbar spine, proximal femur and forearm) were assessed by dual energy X-ray absorptiometry (DXA). Biochemical markers of bone metabolism (serum CTX and osteocalcin) and serum 25(OH)D were also measured. Differences between pre- and postmenopausal women were analyzed by Student´s t-test. Body composition [lean mass, visceral (VAT) and subcutaneous (SAT) adipose tissue] and other potential factors associated with BMD were investigated by multiple regression. Results BMD at all sites evaluated was similar in pre- and postmenopausal women (P > 0.05). Also, no differences between groups were observed for bone turnover markers (P > 0.05). In postmenopausal women, years after menopause was inversely associated with BMD at total body (β = −0.010, P < 0.01) and total femur (β = −0.009, P < 0.05). Serum 25(OH)D was also associated with total femur BMD (β = 0.008, P < 0.01) in postmenopausal women. Lean mass was not associated with BMD in both groups. VAT was directly associated with lumbar spine BMD in postmenopausal women (β = 0.135, P < 0.05). Conclusions Our results suggest that severe obesity may weaken the impact of menopause on bone mass and turnover. Also, soft tissue body composition appears to poorly influence bone density in these women. Funding Sources Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ, Grant number E26/110.764/2013 for FFB).

scholarly journals Obesity and Bone Loss at Menopause: The Role of Sclerostin

Diagnostics ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 1914
Author(s):  
Paolo Marzullo ◽  
Chiara Mele ◽  
Stefania Mai ◽  
Antonio Nardone ◽  
Massimo Scacchi ◽  
...  
Keyword(s):  
Body Composition ◽  
Lumbar Spine ◽  
Femoral Neck ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Health ◽  
Bone Turnover Markers ◽  
Turnover Markers ◽  
Total Body

Background. Peripheral fat tissue is known to positively influence bone health. However, evidence exists that the risk of non-vertebral fractures can be increased in postmenopausal women with obesity as compared to healthy controls. The role of sclerostin, the SOST gene protein product, and body composition in this condition is unknown. Methods. We studied 28 severely obese premenopausal (age, 44.7 ± 3.9 years; BMI, 46.0 ± 4.2 kg/m2) and 28 BMI-matched post-menopausal women (age, 55.5 ± 3.8 years; BMI, 46.1 ± 4.8 kg/m2) thorough analysis of bone density (BMD) and body composition by dual X-ray absorptiometry (DXA), bone turnover markers, sclerostin serum concentration, glucose metabolism, and a panel of hormones relating to bone health. Results. Postmenopausal women harbored increased levels of the bone turnover markers CTX and NTX, while sclerostin levels were non-significantly higher as compared to premenopausal women. There were no differences in somatotroph, thyroid and adrenal hormone across menopause. Values of lumbar spine BMD were comparable between groups. By contrast, menopause was associated with lower BMD values at the hip (p < 0.001), femoral neck (p < 0.0001), and total skeleton (p < 0.005). In multivariate regression analysis, sclerostin was the strongest predictor of lumbar spine BMD (p < 0.01), while menopausal status significantly predicted BMD at total hip (p < 0.01), femoral neck (p < 0.001) and total body (p < 0.05). Finally, lean body mass emerged as the strongest predictor of total body BMD (p < 0.01). Conclusions. Our findings suggest a protective effect of obesity on lumbar spine and total body BMD at menopause possibly through mechanisms relating to lean body mass. Given the mild difference in sclerostin levels between pre- and postmenopausal women, its potential actions in obesity require further investigation.

scholarly journals A Comparison of the Effects of Raloxifene and Estrogen on Bone in Postmenopausal Women1

2000 ◽  
Vol 85 (6) ◽  
pp. 2197-2202
Author(s):  
Karen M. Prestwood ◽  
Michele Gunness ◽  
Douglas B. Muchmore ◽  
Yili Lu ◽  
Mayme Wong ◽  
...  
Keyword(s):  
Lumbar Spine ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Biochemical Markers ◽  
Mineral Density ◽  
Bone Formation Rate ◽  
Markers Of Bone Turnover ◽  
Bone Biopsies ◽  
Hip Bmd ◽  
Total Body

Raloxifene HCl, a selective estrogen receptor modulator, has been shown to increase bone mineral density (BMD) and decrease biochemical markers of bone turnover in postmenopausal women without stimulatory effects on the breast and uterus. However, it is not known whether the changes in BMD and bone turnover are associated with changes at the tissue level, nor how changes with raloxifene compare with estrogen. In this randomized, double blind study, we evaluated the effects of raloxifene (Evista, 60 mg/day) or conjugated equine estrogens (CEE; Premarin, 0.625 mg/day) on bone architecture, bone turnover, and BMD. Iliac crest bone biopsies were obtained at baseline and at the end of the study after double tetracycline labeling and were analyzed for standard histomorphometric indexes. Serum and urinary biochemical markers of bone turnover were measured at baseline and at 4, 10, 18, and 24 weeks of treatment. Total body, lumbar spine, and hip BMD were measured at baseline and at the end of the study by dual energy x-ray absorptiometry. Activation frequency and bone formation rate/bone volume were significantly decreased from baseline in the CEE, but not in the raloxifene, group. Bone mineralization did not change in either group. Most markers of bone resorption and formation decreased in both groups, but to a greater degree in the CEE group (P &lt; .05). Total body and lumbar spine BMD increased from baseline in both groups, with a greater increase in the CEE group (P&lt; 0.05). Hip BMD significantly increased from baseline in the raloxifene group, but the change was not different from that in the CEE group. These results suggest that raloxifene reduces bone turnover and increases bone density, although to a lesser extent than CEE. Thus, raloxifene is an alternative to CEE for the prevention and treatment of osteoporosis in postmenopausal women.

Association of klotho gene polymorphism with bone density and spondylosis of the lumbar spine in postmenopausal women

Bone ◽  
2002 ◽  
Vol 31 (1) ◽  
pp. 37-42 ◽  
Author(s):  
N Ogata ◽  
Y Matsumura ◽  
M Shiraki ◽  
K Kawano ◽  
Y Koshizuka ◽  
...  
Keyword(s):  
Lumbar Spine ◽  
Bone Density ◽  
Gene Polymorphism ◽  
Postmenopausal Women ◽  
Klotho Gene

Weight, body composition, and bone density in postmenopausal women

1996 ◽  
Vol 59 (6) ◽  
pp. 428-432 ◽  
Author(s):  
S. S. Harris ◽  
B. Dawson-Hughes
Keyword(s):  
Body Composition ◽  
Bone Density ◽  
Postmenopausal Women

scholarly journals Genetic polymorphisms and their influence on therapeutic response to alendronate-a pilot study

2019 ◽  
Vol 10 (Vol.10, No.3) ◽  
pp. 243-251
Author(s):  
Alina Deniza CIUBEAN ◽  
Laszlo IRSAY ◽  
Rodica Ana UNGUR ◽  
Viorela Mihaela CIORTEA ◽  
Ileana Monica BORDA ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Lumbar Spine ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Bone Turnover Markers ◽  
Type I Collagen ◽  
Type I ◽  
Mineral Density ◽  
Turnover Markers

Introduction: Osteoporosis has a strong genetic contribution, and several genes have been shown to influence bone mineral density. Variants in the human genome are considered important causes of differences in drug responses observed in clinical practice. In terms of bone mineral density, about 26–53% of patients do not respond to amino-bisphosphonate therapies, of which alendronate is the most widely used. Material and method: The current study is prospective, observational, analytical, longitudinal and cohort type. It included 25 postmenopausal women treated with alendronate for 1 year. Bone mineral density at lumbar spine and proximal femur was measured and bone turnover markers (C-terminal telopeptide of type I collagen and procollagen 1N-terminal propeptide) were evaluated at 0 and 12 months of treatment. Six single nucleotide polymorphisms in osteoporosis-candidate genes were genotyped (FDPS rs2297480, LRP5 rs3736228, SOST rs1234612, VKORC1 rs9934438, GGPS1 rs10925503 and RANKL rs2277439). Treatment response was evaluated by percentage changes in bone mineral density and bone turnover markers. Results: The heterozygous CT of FDPS rs2297480 showed lower increases in BMD values in the lumbar spine region and the homozygous CC of the GGPS1 rs10925503 showed lower increases in terms of BMD at the total hip region. No association was found for LRP5 rs3736228, SOST rs1234612, VKORC1 rs9934438 and RANKL rs2277439. Conclusions: Romanian postmenopausal women with osteoporosis carrying the CT genotype of FDPS rs2297480 or the CC genotype of GGPS1 rs10925503 could have an unsatisfactory response to alendronate treatment. Key words: osteoporosis; genetic polymorphism; alendronate; bone mineral density; bone turnover markers,

Sign in / Sign up

Export Citation Format

Share Document